Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-09 4:49 pm Purchase | 2023-12-31 | 13G | Inventiva S.A. IVA | Sofinnova Crossover I | 6,110,827 9.700% | 2,728,888 (+80.69%) | Filing History |
| 2023-10-30 1:42 pm Purchase | 2023-10-20 | 13D | Abivax SA American Depositary Shares ABVX | Sofinnova Crossover I | 6,948,613 8.000% | 6,948,613 (New Position) | Filing History |
| 2023-02-13 2:08 pm Sale | 2022-12-31 | 13G | MaxCyte, Inc. MXCT | Sofinnova Crossover I | 4,610,693 4.500% | -500,000 (-9.78%) | Filing History |
| 2023-02-13 2:07 pm Purchase | 2022-12-31 | 13G | Inventiva S.A. IVA | Sofinnova Crossover I | 3,381,939 8.000% | 129,032 (+3.97%) | Filing History |
| 2022-02-11 12:00 pm Purchase | 2021-12-31 | 13G | Inventiva S.A. IVA | Sofinnova Crossover I | 3,252,907 6.200% | 138,880 (+4.46%) | Filing History |
| 2022-02-11 10:59 am Purchase | 2021-12-31 | 13G | MaxCyte, Inc. MXCT | Sofinnova Crossover I | 5,110,693 5.100% | 5,110,693 (New Position) | Filing History |
| 2021-02-08 7:30 pm Purchase | 2020-12-31 | 13G | Inventiva S.A. IVA | Sofinnova Crossover I | 3,114,027 10.400% | 3,114,027 (New Position) | Filing History |